Biswas, Swati
Atienza, Philamer
Chipman, Jonathan
Blackford, Amanda L.
Arun, Banu
Hughes, Kevin
Parmigiani, Giovanni
Funding for this research was provided by:
National Cancer Institute (1R03CA173834-02, 2P30CA006516-47)
Article History
Received: 7 January 2016
Accepted: 9 January 2016
First Online: 19 January 2016
Compliance with ethical standards
:
: Kevin Hughes is a founder of and has a financial interest in Hughes Risk Apps (HRA), LLC. Dr. Hughes’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Kevin Hughes has received honoraria from Myriad Genetics Speaker’s Bureau and holds stock options in 5 AM solutions. GP is on the SAB of HRA and holds stock options in the company.